Arcus Biosciences (NYSE:RCUS) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Arcus Biosciences (NYSE:RCUS) in a research report report published on Friday morning, Benzinga reports.

Several other equities research analysts have also recently commented on the company. Wedbush reissued an outperform rating and issued a $30.00 price target on shares of Arcus Biosciences in a research note on Friday. Citigroup boosted their price target on Arcus Biosciences from $36.00 to $38.00 and gave the company a buy rating in a research note on Monday, June 3rd. Barclays lowered their price target on Arcus Biosciences from $35.00 to $25.00 and set an overweight rating for the company in a research note on Monday, July 8th. Finally, Truist Financial decreased their target price on Arcus Biosciences from $50.00 to $44.00 and set a buy rating for the company in a research report on Monday, June 24th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $38.11.

Arcus Biosciences Trading Up 14.0 %

NYSE:RCUS traded up $1.92 on Friday, hitting $15.61. 827,381 shares of the company’s stock traded hands, compared to its average volume of 513,982. The company has a market cap of $1.42 billion, a PE ratio of -5.02 and a beta of 0.90. The firm has a 50-day moving average price of $15.30 and a 200-day moving average price of $16.24. Arcus Biosciences has a 1 year low of $12.95 and a 1 year high of $25.47.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, meeting the consensus estimate of ($1.02). The business had revenue of $39.00 million during the quarter, compared to analysts’ expectations of $26.24 million. Arcus Biosciences had a negative return on equity of 40.98% and a negative net margin of 97.47%. The firm’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.04) EPS. On average, research analysts forecast that Arcus Biosciences will post -3.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RCUS. GAMMA Investing LLC acquired a new position in shares of Arcus Biosciences during the fourth quarter worth approximately $31,000. Spartan Fund Management Inc. acquired a new position in shares of Arcus Biosciences during the first quarter worth approximately $38,000. Headlands Technologies LLC acquired a new position in shares of Arcus Biosciences during the first quarter worth approximately $59,000. Innealta Capital LLC acquired a new position in shares of Arcus Biosciences during the second quarter worth approximately $66,000. Finally, Cape Investment Advisory Inc. acquired a new position in shares of Arcus Biosciences during the fourth quarter worth approximately $77,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.